Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-Blind, Active-Controlled,Phase 2/3 Study to Determine the Short-Term (6-Week) and Long-Term (6 Month) Cognitive and Anti-Psychotic Efficacy, Safety and Tolerability of CYP-1020 Compared to Risperidone in Patients With Schizophrenia

NCT01363349 is registered in ClinicalTrials.gov with BioLineRx, Ltd. as lead sponsor.

NCT NCT01363349
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01363349 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-Blind, Active-Controlled,Phase 2/3 Study to Determine the Short-Term (6-Week) and Long-Term (6 Month) Cognitive and Anti-Psychotic Efficacy, Safety and Tolerability of CYP-1020 Compared to Risperidone in Patients With Schizophrenia
Lead sponsor
BioLineRx, Ltd.
Phase
Phase 2/3
Overall status
Terminated
Start date
May 31, 2011
Completion date
April 30, 2013
Enrollment
269 (actual)
Sites
39

Conditions

As the registry lists them; a condition with its own page is linked.

cognitive effect on schizophrenic patients, schizophrenia